📈 Live Market Tracking
Every NSE and BSE corporate filing, read and explained by AI within minutes — impact, key figures, short/long-term view and what to watch.
Live · AI analyzer runs every 5 min (07:00–23:55 IST)
Latest filing: 2026-08-22 14:03
298 analysed today
FollowTelegram
298
Today
149,699
All-time analysed
42,924
Positive
6,662
Negative
91,432
Neutral
8,613
Watch
📊 Last 7 days — analysed filings by sentiment
Note: These are AI-generated, educational summaries of public NSE
filings — grounded in each document, but not investment advice and possibly incomplete.
Verify against the original filing and consult a SEBI-registered adviser before acting.
3 announcements match the current filters (relevance ≥ 5).
Bansisons Tea Renames to Novyra Pharmachem Limited Amid Pivot into Pharma & CDMO
Bansisons Tea Industries Limited has officially received approval to change its corporate name to 'Novyra Pharmachem Limited' effective from January 19, 2026. The name change signals a business pivot from tea into pharmaceuticals, life sciences, API manufacturing, specialty chemicals, and CRO/CDMO services. The company is a micro-cap with a market capitalization of Rs 7 Cr, which reported FY26 revenue of Rs 0.1 Cr and a net loss of Rs -5.37 Cr. Investors should note that while the corporate identity has shifted, no concrete capital outlay, plant locations, or execution timelines were quantified in this filing.
Confidence: HIGH
What changedBansisons Tea has formally changed its name to Novyra Pharmachem Limited to reflect a business pivot to pharmaceuticals and CDMO services.
Why it mattersThe company with TTM revenue of Rs 2 Cr is pivoting out of its legacy tea business into capital-intensive pharma manufacturing, which alters its fundamental risk and operating profile.
Application Date: 16 July 2026Name Approval Date: 22 August 2026Certificate Issuance Date: 19 January 2026Market Cap: Rs 7 Cr
📅 Short termStock exchange ticker and name change processing across depositories and BSE.
📈 Long termSuccess depends entirely on tangible investments, setup of compliant manufacturing infrastructure, and commercial traction in the API/CDMO space.
⚠ Risk flags
- Major business pivot into highly regulated and capital-intensive pharma/CDMO sector
- Low net worth (Rs 1 Cr) and track record of net losses (FY26 net loss of Rs -5.37 Cr)
- Lack of detailed capex or funding roadmap in the announcement
Key Highlights
Corporate name changed from 'Bansisons Tea Industries Limited' to 'Novyra Pharmachem Limited'
Approval received on 22 August 2026 pursuant to an application dated 16 July 2026
Certificate of Incorporation issued by the RoC Central Processing Centre on 19 January 2026
Pivoting operations into active pharmaceutical ingredients (APIs), bulk drugs, and CDMO/CRO services
👀 What to Watch
Track subsequent exchange filings for concrete capital expenditure plans, regulatory manufacturing licenses (e.g., USFDA/GMP), and quarterly revenue contributions from the new pharma business.
Bansisons Tea Q1 Revenue at ₹1.73 Cr; Net Loss Narrows to ₹0.02 Cr
Novyra Pharmachem (formerly Bansisons Tea Industries) reported standalone revenue from operations of ₹1.73 Cr (₹172.61 lakhs) for the quarter ended June 30, 2026, compared to ₹0.10 Cr in the preceding quarter and ₹0.03 Cr in Q1 FY26. Net loss narrowed substantially to ₹0.02 Cr (₹1.99 lakhs) from a loss of ₹5.34 Cr in Q4 FY26. Total revenue was entirely generated from the Pharma segment, while the legacy Tea Estate and Real Estate segments reported zero revenue. Basic and diluted EPS for the quarter stood at ₹(0.03).
Confidence: HIGH
What changedThe company reported a sharp sequential uptick in revenue driven entirely by pharma segment activity, while net losses narrowed near break-even.
Why it mattersDemonstrates a shift away from legacy tea estate business toward pharma trading, which has revived top-line revenue after multi-quarter stagnation.
Revenue from operations: ₹172.61 lakhsNet Loss: ₹(1.99) lakhsPharma segment revenue: ₹172.61 lakhsBasic EPS: ₹(0.03)Paid-up equity share capital: ₹633.00 lakhs
📅 Short termSequential narrowing of losses and top-line pickup provide positive operational traction in the near term.
📈 Long termStructural revival depends on achieving consistent profitability and scaling the newly transitioned pharma operations.
⚠ Risk flags
- Low promoter holding (23.15%)
- Micro-cap size with low liquidity
- Complete reliance on a newly entered business segment
Key Highlights
Revenue from operations rose to ₹1.73 Cr (₹172.61 lakhs) in Q1 FY27 from ₹0.10 Cr in Q4 FY26
Net loss narrowed significantly to ₹0.02 Cr (₹1.99 lakhs) from ₹5.34 Cr in the preceding quarter
Pharma segment contributed 100% of the operational revenue at ₹172.61 lakhs
Quarterly EPS improved to ₹(0.03) compared to ₹(8.43) in Q4 FY26
👀 What to Watch
Track whether the revenue ramp-up in the pharma segment sustains over upcoming quarters and monitor progress toward operating profitability.
Novyra Pharmachem Q1: Revenue at Rs 1.73 Cr, Net Loss Narrows to Rs 0.02 Cr
Novyra Pharmachem Ltd (formerly Bansisons Tea Industries Ltd) reported standalone revenue from operations of Rs 1.73 Cr (Rs 172.61 lakhs) for the quarter ended June 30, 2026, compared to Rs 0.03 Cr in the year-ago period. The operational revenue was entirely driven by the Pharma business segment. Standalone net loss narrowed significantly to Rs 0.02 Cr (Rs 1.99 lakhs) from a net loss of Rs 5.34 Cr in the preceding quarter (Q4 FY26). Total expenses stood at Rs 1.75 Cr, primarily driven by stock-in-trade purchases of Rs 1.89 Cr.
Confidence: HIGH
What changedThe company reported Q1 results reflecting an operational shift into the pharma business, driving revenue up to Rs 1.73 Cr and cutting net loss to Rs 0.02 Cr.
Why it mattersDemonstrates initial revenue traction under the revamped business operations following previous heavy losses, though profitability is yet to break even.
Revenue from operations (Q1): Rs 172.61 lakhsNet Loss (Q1): Rs (1.99) lakhsPharma Segment Revenue: Rs 172.61 lakhsStock-in-trade Purchases: Rs 189.13 lakhsPaid-up Equity Capital: Rs 633.00 lakhs
📅 Short termThe sharp reduction in quarterly losses and visible top-line contribution from the pharma division provide near-term relief after previous heavy losses.
📈 Long termStructural turnaround depends on building sustained, margin-positive operations in the pharma trading/manufacturing business.
⚠ Risk flags
- History of substantial quarterly losses (Rs -5.34 Cr in Q4 FY26)
- Low promoter shareholding at 23.15%
- Business transition risk into pharma with limited operational history
Key Highlights
Standalone revenue from operations stood at Rs 172.61 lakhs for Q1 ended June 30, 2026 vs Rs 3.00 lakhs in Q1 ended June 30, 2025.
Net loss sharply reduced to Rs 1.99 lakhs compared to a loss of Rs 533.83 lakhs in the preceding quarter.
Pharma segment contributed the entirety of segment revenue at Rs 172.61 lakhs, with Real Estate and Tea segments generating nil revenue.
Basic and diluted EPS stood at Rs -0.03 per share vs Rs -8.43 in Q4 FY26.
👀 What to Watch
Monitor whether the company can maintain revenue momentum in the pharma segment and achieve sustainable positive operating margins in subsequent quarters.
